Press "Enter" to skip to content

Beam Therapeutics Adds To Drug Delivery With $120M GuideTx Buy

  • Beam Therapeutics Inc (NASDAQ: BEAM) acquires Guide Therapeutics (GuideTx), a developer of nonviral drug delivery vehicles for genetic medicines, in an all-stock deal for $120 million upfront. GuideTx shareholders could also yield up to $320 million more in milestone payments.
  • Beam is betting that adding GuideTx’s lipid nanoparticle (LNP) drug delivery vehicles to the mix will boost its genetic medicines’ reach into new tissues and disease areas.
  • GuideTx’s LNP screening technology tags nanoparticles with DNA barcodes allows hundreds of nanoparticles to be screened in one experiment, in a single animal.
  • So far, GuideTx has identified a library of lipids and lipid formulations that could ramp up the development of gene editing treatments to tissues other than the liver.
  • Price Action: BEAM is down 14.4% at $94.56 in market trading hours on the last check Tuesday.

This post was originally published on this site

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *